Concr announces partnership with CariGenetics
Concr, a deeptech company dedicated to enabling precision medicine and improving drug development using predictive analytics and artificial intelligence (AI), has announced its partnership with CariGenetics. Through this collaboration, Concr and CariGenetics will expand use of vital genetic and molecular data on Triple Negative Breast Cancer (TNBC) from the Caribbean region, filling a critical gap in diversity for global healthcare and the pharmaceutical industry.
Read the full news story about Concr's partnership with CariGenetics.
